---
title: "Obefazimod (ABX464) in Ulcerative colitis: Pharmacokinetics"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Pharmacokinetics. Topics: Absorption and conversion to the N-glucuronide metabolite: first-in-human single ascending dose study, Half-lives of the parent compound and the metabolite after repeated doses, Metabolism by glucuronidation and time to steady state, Effect of food on exposure, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Absorption and conversion to the N-glucuronide metabolite: first-in-human single ascending dose study

> “A single oral dose of ABX464 (50, 100, 150 or 200 mg) was administered on the morning of day 0 after overnight fasting, with follow-up for 45 days.”
> “ABX464's C max was observed approximately 2 h after administration in all groups.”
> “ABX464 was rapidly and substantially metabolized into ABX464-NGlc.”
> “The C max of ABX464-NGlc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer t 1/2 (90-110 h).”
> “The ratio of metabolite to parent drug was consistent across the complete dose range.”

Source: [Scherrer et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27999038/)

<a id="topic-2.1.2.6.3-2"></a>

### Half-lives of the parent compound and the metabolite after repeated doses

> “ABX464 was rapidly eliminated with a half-life (t1/2) of about 1 h, while its metabolite, ABX464-NGlc, was very slowly cleared with a t1/2 of about 100 h.”

Source: [Steens et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5487684/)

<a id="topic-2.1.2.6.3-3"></a>

### Metabolism by glucuronidation and time to steady state

> “In humans, obefazimod is metabolized via glucuronidation to ABX464-N-Glu, which contributes the majority of plasma exposure.”
> “After repeated administration of obefazimod, an initial decrease in obefazimod plasma area under the curve was observed until steady state was reached after 4 weeks of treatment.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.6.3-4"></a>

### Effect of food on exposure

> “The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively).”
> “The apparent terminal elimination half-lives (t1/2s) under fed and fasted conditions were comparable, at about 0.80 h.”
> “The median time to maximum concentration (Tmax) was delayed from 1.5 to 2.8 h, and the ratio of the AUC0–∞ obtained under fed conditions to the AUC0–∞ obtained under fasted conditions (Frel) was 2.69.”
> “The increases in Cmax and AUC0–∞ of the metabolite ABX464–N-glucuronide (ABX464-NGlc) were, however, much more limited when ABX464 was given with food.”
> “The t1/2s were also comparable under the two conditions (around 100 h).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

> “Food intake prior to administration significantly increased obefazimod exposure, by at least 3- to 4-fold.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-2.1.2.6.3-5"></a>

### Interindividual variability under fed and fasted conditions

> “Interindividual variability tended to decrease when ABX464 was given with food, since the CVs of AUC0–t and AUC0–∞ under fasted conditions were 67% and 57% compared to 42% and 37%, respectively, under fed conditions.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

Additional sources: [ClinicalTrials.gov NCT05032560](https://clinicaltrials.gov/study/NCT05032560)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
